Every material Form 8-K Colgate-Palmolive has filed with the SEC since October 27, 2023, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Colgate-Palmolive reported third quarter 2026 net sales of $5.37 billion, representing a 4.6% increase year over year, with GAAP earnings per share of $0.94. Driven by ongoing sales momentum and margin expansion, the company raised its full-year earnings per share growth guidance to 5% to 7% on a non-GAAP basis.
Net sales rose 4.6% to $5,369 million for the quarter ended September 30, 2026.
GAAP EPS increased 3% to $0.94, while Base Business EPS grew 7% to $0.97.
Full-year 2026 organic sales growth is now expected to be broadly in line with its nine-month performance.
Colgate-Palmolive reported second-quarter 2026 net sales of $5,361 million, up 4.9% from $5,110 million, and GAAP diluted EPS of $0.86, down 5% from $0.91. Excluding a $129 million charge tied to its Strategic Growth and Productivity Program, Base Business EPS rose 8% to $0.99, and the company updated its full-year 2026 gross margin and Base Business EPS guidance upward while keeping its sales and GAAP EPS guidance.
Net sales rose 4.9% to $5,361 million; organic sales rose 2.4%, and Total Company operating profit fell 6% to $1,016 million.
GAAP gross profit margin rose 140 basis points to 61.5%; Base Business EPS rose 8% to $0.99 from $0.92.
Full-year 2026 guidance: GAAP and Base Business gross profit margin now expected roughly flat (previously down); Base Business EPS growth now expected mid-single-digit (previously low- to mid-single-digit).
Net sales guidance of up 2% to 6% and GAAP EPS guidance were maintained.
Colgate-Palmolive reported first-quarter 2026 net sales of $5,324 million, up 8.4%, while GAAP diluted EPS fell 6% to $0.80 and base business EPS rose 7% to $0.97. On April 30, 2026, the board expanded its Strategic Growth and Productivity Program, raising estimated cumulative pretax charges to $350 million to $550 million from $200 million to $300 million.
Net sales rose to $5,324 million from $4,911 million; organic sales grew 2.9%.
GAAP diluted EPS was $0.80 versus $0.85; base business EPS was $0.97 versus $0.91.
Program charges now estimated at $350 million to $550 million, with $200 million to $300 million in annual savings once implemented.
Full-year 2026 sales and EPS guidance was maintained, but GAAP and base business gross profit margin is now expected to decline, versus a prior expectation of an increase.
Colgate-Palmolive said its Board elected Betsy Fishbone, currently Executive Vice President and Deputy Chief Legal Officer, as Chief Legal Officer and Secretary, effective June 1, 2026. Jennifer M. Daniels, who has held the role since 2014, plans to retire in 2026 and will become Vice Chair on the same date to oversee an orderly handover.
Betsy Fishbone to become Chief Legal Officer and Secretary effective June 1, 2026
Jennifer M. Daniels, Chief Legal Officer and Secretary since 2014, intends to retire in 2026
Daniels to be elected Vice Chair effective June 1, 2026 to provide for an orderly transition
Board action taken April 8, 2026; filing dated April 9, 2026
Colgate-Palmolive's board elected Christopher S. Boerner, chair and chief executive of Bristol Myers Squibb, as a director effective March 15, 2026. Separately, director Steven A. Cahillane will not stand for reelection at the May 8, 2026 annual meeting because of his new role as chief executive of The Kraft Heinz Company. The filing describes board composition changes only and gives no financial results or operating impact.
Christopher S. Boerner, 55, joins the board effective March 15, 2026; he has been Bristol Myers Squibb CEO since November 2023 and board chair since April 2024
Steven A. Cahillane will not seek reelection to the board at the Annual Meeting of Stockholders on May 8, 2026
Cahillane cited the demands of his new position as CEO of The Kraft Heinz Company
Boerner will receive non-employee director compensation under the program described in the March 26, 2025 proxy statement
Colgate-Palmolive reported fourth quarter 2025 net sales up 5.8% to $5,230 million, but GAAP diluted EPS was $(0.05) versus $0.90 a year earlier, driven by a $794 million after-tax goodwill and intangible asset impairment tied to the skin health business. Excluding these items, Base Business EPS rose 4% to $0.95. The company also guided 2026 net sales growth of 2% to 6% and GAAP double-digit EPS growth.
Q4 2025 net sales rose 5.8% to $5,230 million; organic sales rose 2.2%.
GAAP diluted EPS was $(0.05), down 106%, after a $794 million after-tax impairment charge on skin health goodwill and intangibles.
Base Business EPS rose 4% to $0.95; full-year 2025 GAAP EPS fell 25% to $2.63.
2026 guidance: net sales up 2% to 6%, organic sales growth of 1% to 4%, and GAAP double-digit EPS growth.
Colgate-Palmolive reported third quarter 2025 net sales of $5.1 billion, up 2.0%, and GAAP diluted EPS of $0.91, up 1%, though organic sales rose only 0.4%. The company lowered its full-year organic sales growth outlook to 1% to 2% from the low end of 2% to 4%, kept its EPS outlook, and disclosed a three-year productivity program with $200 million to $300 million of pre-tax charges, substantially all incurred by December 31, 2028.
Q3 2025 net sales $5,131 million, up 2.0%; organic sales up 0.4%
GAAP diluted EPS $0.91 versus $0.90 a year earlier; GAAP gross profit margin 59.4%, down 170 basis points
Full-year 2025 organic sales growth now expected at 1% to 2%, versus the low end of 2% to 4% previously; EPS still expected up low single digits
Strategic Growth and Productivity Program: cumulative pre-tax charges of $200 million to $300 million, with about 75% to 85% expected to be cash expenditures
Colgate-Palmolive reported second-quarter 2025 net sales of $5,110 million, up 1.0%, and GAAP diluted EPS of $0.91, up 2%, while narrowing its full-year organic sales growth outlook to the low end of 2% to 4%. The company also approved a three-year productivity program with projected pre-tax charges of $200 million to $300 million, which will weigh on reported results through December 31, 2028.
Q2 2025 net sales were $5,110 million, up 1.0%; organic sales rose 1.8%, including a 0.6% negative impact from lower private label pet sales.
GAAP diluted EPS was $0.91, up from $0.89; GAAP gross profit margin fell 50 basis points to 60.1%.
Full-year 2025 organic sales growth is now expected at the low end of 2% to 4%; GAAP EPS is still expected to rise low single digits.
The productivity program carries projected cumulative pre-tax charges of $200 million to $300 million over three years, with substantially all incurred by December 31, 2028, recorded in the Corporate segment.
Colgate-Palmolive's board elected Shane Grant, formerly of Group Danone, as Chief Operating Officer, Americas, effective June 16, 2025, with a base salary of $1,100,000 and a target bonus of 115% of salary. The filing also says Prabha Parameswaran will become Vice Chair and retire on October 1, 2025, and names new operating and growth roles for two other executives.
Shane Grant, 50, joins from Group Danone, where he was Group Deputy CEO and CEO Americas; he will report to CEO Noel R. Wallace
Grant's package includes a 90,000-unit restricted stock unit replacement award and a $1,000,000 sign-on bonus plus a $1,500,000 transition allowance
Prabha Parameswaran, Group President, Growth and Strategy, plans to retire October 1, 2025 and becomes Vice Chair effective June 16, 2025
Panagiotis Tsourapas and John Hazlin receive promotions to Chief Operating Officer roles and Chief Growth Officer, respectively, effective June 16, 2025
Colgate-Palmolive reported first-quarter 2025 results with net sales down 3.1% to $4,911 million, mainly because foreign exchange was a 4.4% headwind, while organic sales rose 1.4%. GAAP diluted EPS rose 2% to $0.85, and the company updated its full-year 2025 guidance, now expecting organic sales growth of 2% to 4% and EPS up low single digits on a GAAP basis.
Net sales were $4,911 million, down 3.1% from $5,065 million; foreign exchange was a 4.4% headwind.
GAAP diluted EPS was $0.85 versus $0.83; Base Business (non-GAAP) EPS was $0.91 versus $0.86.
For full-year 2025, the company now expects organic sales growth of 2% to 4% and GAAP EPS up low single digits.
Hill's operating profit rose 30% to $258 million, while Latin America net sales fell 8.7%.
Colgate-Palmolive reported fourth quarter and full year 2024 results. Fourth quarter net sales were $4,944 million, down 0.1%, while GAAP diluted EPS rose 3% to $0.90. For the full year, net sales reached $20.1 billion (up 3.3%) and GAAP diluted EPS rose 27% to $3.51. For 2025, the company expects roughly flat net sales and mid-single-digit GAAP EPS growth.
Q4 2024 net sales $4,944 million, down 0.1%; organic sales up 4.3%
Q4 2024 GAAP diluted EPS $0.90, up 3%; Base Business EPS $0.91, up 5%
Full year 2024 net sales $20.1 billion, up 3.3%; GAAP diluted EPS $3.51, up 27%
2025 guidance: net sales roughly flat, including a mid-single-digit negative FX impact; GAAP EPS growth mid-single-digit
Colgate-Palmolive reported second quarter 2024 net sales of $5,058 million, up 4.9%, and GAAP diluted EPS of $0.89, up 48% from $0.60. The company raised its full-year 2024 organic sales growth guidance to 6% to 8% and its Base Business EPS growth guidance to 8% to 11%.
Organic sales grew 9.0% in the quarter; Base Business EPS rose 18% to $0.91
GAAP gross profit margin rose 280 basis points to 60.6%
Full-year 2024 organic sales growth guidance raised to 6% to 8% from 5% to 7%
Net sales growth guidance of 2% to 5% unchanged, including a mid-single-digit negative foreign exchange impact
Colgate-Palmolive reported first-quarter 2024 net sales of $5,065 million, up 6.2%, and GAAP diluted EPS of $0.83, up 84% from $0.45. The company raised its full-year 2024 net sales and organic sales growth guidance, which supports the outlook for shareholders.
Net sales rose 6.2% to $5,065 million; organic sales rose 9.8%.
GAAP diluted EPS was $0.83 versus $0.45; Base Business EPS (non-GAAP) was $0.86 versus $0.73.
Full-year 2024 net sales growth guidance raised to 2% to 5% from 1% to 4%; organic sales growth guidance raised to 5% to 7% from 3% to 5%.
Net cash provided by operations was $681 million for the first three months of 2024.
Colgate-Palmolive's board elected Brian Newman, Executive Vice President and Chief Financial Officer of United Parcel Service, to its board, effective March 15, 2024. Director Stephen I. Sadove, 72, will retire at the end of his current term under the company's mandatory retirement policy and will not stand for reelection at the May 10, 2024 annual meeting.
Brian Newman, 55, joins the board effective March 15, 2024; he has been with UPS since 2019 and previously spent 26 years at PepsiCo.
Newman will receive non-employee director compensation under the program described in the proxy statement filed March 29, 2023.
Stephen I. Sadove, 72, will leave the board at the end of his current term, per the mandatory retirement policy.
The Annual Meeting of Stockholders is scheduled for May 10, 2024.
Colgate-Palmolive reported fourth-quarter 2023 net sales of $4,950 million, up 7.0% from a year earlier, and GAAP diluted EPS of $0.87 versus $0.01, which lapped 2022 impairment charges. For full year 2023, net sales rose 8.5% to $19,457 million and GAAP diluted EPS rose 30% to $2.77. The company guided 2024 net sales growth of 1% to 4% and double-digit GAAP EPS growth.
4Q 2023 net sales $4,950 million, up 7.0%; diluted EPS $0.87 versus $0.01 in 4Q 2022
Full-year 2023 net sales $19,457 million, up 8.5%; diluted EPS $2.77 versus $2.13
2024 guidance: net sales growth of 1% to 4% and double-digit GAAP EPS growth, including a low-single-digit negative foreign exchange impact
Colgate-Palmolive reported third quarter 2023 net sales of $4,915 million, up 10.5% from a year earlier, and GAAP diluted earnings per share of $0.86, up 16% from $0.74. The company raised its full-year 2023 financial guidance for net sales growth and organic sales growth, which signals higher expected results for shareholders.
Third quarter 2023 net sales were $4,915 million, up 10.5% from $4,455 million in the year-earlier quarter.
GAAP diluted EPS was $0.86 versus $0.74, up 16%; Base Business (non-GAAP) EPS also rose 16% to $0.86.
Full-year 2023 net sales growth guidance was raised to 6% to 8% from 5% to 8%.
Full-year 2023 organic sales growth guidance was raised to 7% to 8% from 5% to 7%.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Colgate-Palmolive filing is on SEC EDGAR ↗. 8-K briefs of other companies →